Your browser is no longer supported. Please, upgrade your browser.
VIE Viela Bio, Inc. daily Stock Chart
Viela Bio, Inc.
Index- P/E- EPS (ttm)-3.18 Insider Own56.90% Shs Outstand52.21M Perf Week-1.85%
Market Cap1.38B Forward P/E- EPS next Y-2.62 Insider Trans-4.09% Shs Float24.52M Perf Month-20.24%
Income-139.60M PEG- EPS next Q-0.75 Inst Own45.80% Short Float11.37% Perf Quarter-38.17%
Sales30.00M P/S45.87 EPS this Y38.40% Inst Trans31.75% Short Ratio13.46 Perf Half Y-30.33%
Book/sh8.43 P/B3.14 EPS next Y13.20% ROA-38.70% Target Price- Perf Year-
Cash/sh8.19 P/C3.23 EPS next 5Y- ROE-65.60% 52W Range18.20 - 70.66 Perf YTD-2.47%
Dividend- P/FCF- EPS past 5Y- ROI-25.30% 52W High-60.93% Beta-
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low51.70% ATR2.32
Employees139 Current Ratio10.70 Sales Q/Q- Oper. Margin- RSI (14)40.22 Volatility7.09% 8.29%
OptionableNo Debt/Eq0.00 EPS Q/Q-588.30% Profit Margin- Rel Volume0.76 Prev Close26.48
ShortableYes LT Debt/Eq0.00 EarningsAug 12 AMC Payout- Avg Volume207.14K Price27.61
Recom2.00 SMA20-9.73% SMA50-19.16% SMA200-29.53% Volume156,863 Change4.27%
Aug-13-20Reiterated H.C. Wainwright Buy $76 → $82
Jul-15-20Upgrade Goldman Sell → Neutral $48 → $49
Jun-09-20Initiated Stifel Hold $58
May-14-20Reiterated H.C. Wainwright Buy $60 → $70
Apr-29-20Initiated Wedbush Outperform $62
Apr-06-20Downgrade Goldman Neutral → Sell $36
Feb-18-20Initiated H.C. Wainwright Buy $60
Feb-04-20Downgrade Goldman Buy → Neutral $36
Oct-28-19Initiated Morgan Stanley Overweight $25
Oct-28-19Initiated Guggenheim Buy $44
Oct-28-19Initiated Goldman Buy $32
Oct-28-19Initiated Cowen Outperform
Sep-03-20 04:01PM  
Aug-13-20 05:00AM  
Aug-12-20 04:15PM  
Aug-05-20 07:00AM  
Jun-12-20 02:07PM  
Jun-11-20 05:45PM  
May-27-20 10:41PM  
May-26-20 07:24AM  
May-15-20 12:51PM  
May-14-20 11:00AM  
May-13-20 04:15PM  
May-12-20 01:09PM  
May-06-20 07:00AM  
Apr-30-20 04:15PM  
Mar-25-20 04:15PM  
Mar-18-20 09:38AM  
Mar-11-20 09:32AM  
Feb-26-20 08:42AM  
Dec-11-19 07:00AM  
Nov-14-19 04:00PM  
Nov-12-19 11:40AM  
Oct-11-19 05:01PM  
Oct-09-19 06:00AM  
Oct-07-19 04:05PM  
Oct-03-19 02:49PM  
Oct-02-19 09:54PM  
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjogren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hu EdwardDirectorJun 05Sale44.18180,0007,952,400208,059Jun 09 04:52 PM
Boundless Meadow Ltd10% OwnerJun 05Sale47.00360,00016,920,0008,622,353Jun 08 09:14 PM
Cao YanlingDirectorJun 05Sale47.00360,00016,920,0008,322,353Jun 08 09:12 PM
Tong XiaomengDirectorJun 05Sale47.00360,00016,920,0008,622,353Jun 08 09:13 PM
Ragatz WilliamVP, Head of CommercialJan 27Option Exercise5.2216,25084,82516,250Jan 29 06:33 PM